Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 321 DKK 2.01% Market Closed
Market Cap: 84.7B DKK

EV/EBITDA
Enterprise Value to EBITDA

31.6
Current
31.2
Median
3.9
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
31.6
=
Enterprise Value
80.6B DKK
/
EBITDA
2.5B DKK
EBITDA Growth EV/EBITDA to Growth
DK
Genmab A/S
CSE:GMAB
Average EV/EBITDA: 17.6
31.6
126%
0.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -204 636.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.5
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.4
7%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -552.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
14%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -615.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
9
2-Years Forward
EV/EBITDA
7.6
3-Years Forward
EV/EBITDA
6.2